UBS Sticks to Their Hold Rating for Bayer (0P6S)
UBS analyst Matthew Weston maintained a Hold rating on Bayer today and set a price target of €48.00.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
According to TipRanks, Weston is a 4-star analyst with an average return of 13.4% and a 75.26% success rate. Weston covers the Healthcare sector, focusing on stocks such as Novo Nordisk, GlaxoSmithKline, and Roche Holding AG.
In addition to UBS, Bayer also received a Hold from Jefferies’s Chris Counihan in a report issued on February 17. However, on February 18, Goldman Sachs maintained a Buy rating on Bayer (LSE: 0P6S).
The company has a one-year high of €49.78 and a one-year low of €18.38. Currently, Bayer has an average volume of 3.72M.
Read More on GB:0P6S:
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.